[Lowering LDL-cholesterol: the lower the better?]

Area of Science:

• Cardiovascular Medicine
• Clinical Research Methodology
• Pharmacological Treatment

Background:

• The optimal low-density lipoprotein (LDL) cholesterol target for pharmacological treatment is debated.
• Current evidence presents conflicting views, with some advocating for the 'lower the better' approach and others suggesting a threshold of < 2.5 mmol/l is sufficient.

Purpose of the Study:

• To evaluate whether achieving very low LDL levels (< 1.8 mmol/l) confers a lower vascular risk compared to LDL levels between 1.8 and 2.5 mmol/l.
• To emphasize the critical role of study design and adjustment for confounding factors in determining treatment efficacy.

Main Methods:

• Analysis of two recent studies published in JAMA, examining their methodologies and conclusions regarding LDL cholesterol targets.
• Focus on the importance of individual participant data for robust confounding adjustment versus using group-level mean data.

Main Results:

• One study, utilizing individual participant data, found no additional benefit for LDL levels below 2.5 mmol/l.
• The other study, based on group-level data, supported the 'lower the better' hypothesis but lacked adequate adjustment for confounding variables.

Conclusions:

• Study design is paramount in cardiovascular research, particularly concerning the adjustment for confounding factors.
• The interpretation of LDL cholesterol's impact on vascular risk is highly dependent on the methodological rigor of the study.
• Further research with robust designs is needed to definitively establish optimal LDL targets.